Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALBIOSS-BALANCED: Albumin and Balanced Solutions in Septic Shock
NCT03654001Phase 3Completed
- Sponsor
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
- Start
- May 2019
- Primary completion
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of albumin (human) in septic shock (4 arms), sponsored by Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico. Primary endpoints: All-cause 90-day mortality and Incidence of Acute Kidney Injury at 90 days. Started May 2019; status: completed.
02
Drugs
albumin (human)
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT03654001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03654001.